AbbVie (ABBV) Competitors

Eli Lilly and Company (NYSE:LLY) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, community ranking, analyst recommendations, dividends, earnings, media sentiment and risk.

Do institutionals & insiders believe in LLY or ABBV?

82.5% of Eli Lilly and Company shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 0.1% of Eli Lilly and Company shares are owned by company insiders. Comparatively, 0.3% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Do analysts rate LLY or ABBV?

Eli Lilly and Company presently has a consensus price target of $1,002.80, indicating a potential upside of 21.54%. AbbVie has a consensus price target of $211.41, indicating a potential upside of 6.44%. Given Eli Lilly and Company's higher possible upside, equities analysts plainly believe Eli Lilly and Company is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eli Lilly and Company	1 Sell rating(s)	2 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.81
AbbVie	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	3 Strong Buy rating(s)	2.89

Is LLY or ABBV a better dividend stock?

Eli Lilly and Company pays an annual dividend of $6.00 per share and has a dividend yield of 0.7%. AbbVie pays an annual dividend of $6.56 per share and has a dividend yield of 3.3%. Eli Lilly and Company pays out 51.2% of its earnings in the form of a dividend. AbbVie pays out 279.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Eli Lilly and Company has increased its dividend for 11 consecutive years and AbbVie has increased its dividend for 53 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Which has more volatility and risk, LLY or ABBV?

Eli Lilly and Company has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500.

Does the media prefer LLY or ABBV?

In the previous week, Eli Lilly and Company had 35 more articles in the media than AbbVie. MarketBeat recorded 133 mentions for Eli Lilly and Company and 98 mentions for AbbVie. AbbVie's average media sentiment score of 1.02 beat Eli Lilly and Company's score of 0.69 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eli Lilly and Company	61 Very Positive mention(s)	21 Positive mention(s)	30 Neutral mention(s)	11 Negative mention(s)	6 Very Negative mention(s)	Positive
AbbVie	54 Very Positive mention(s)	3 Positive mention(s)	25 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer LLY or ABBV?

AbbVie received 129 more outperform votes than Eli Lilly and Company when rated by MarketBeat users. Likewise, 73.46% of users gave AbbVie an outperform vote while only 70.64% of users gave Eli Lilly and Company an outperform vote.

Company	Underperform	Outperform
Eli Lilly and Company	Outperform Votes 1227 70.64%	Underperform Votes 510 29.36%
AbbVie	Outperform Votes 1356 73.46%	Underperform Votes 490 26.54%

Which has better earnings and valuation, LLY or ABBV?

Eli Lilly and Company has higher earnings, but lower revenue than AbbVie. Eli Lilly and Company is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eli Lilly and Company	$45.04B	17.37	$10.59B	$11.71	70.46
AbbVie	$57.37B	6.12	$4.28B	$2.35	84.52

Is LLY or ABBV more profitable?

Eli Lilly and Company has a net margin of 23.51% compared to AbbVie's net margin of 7.59%. AbbVie's return on equity of 296.28% beat Eli Lilly and Company's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eli Lilly and Company	23.51%	85.24%	16.19%
AbbVie	7.59%	296.28%	12.65%

Summary

AbbVie beats Eli Lilly and Company on 12 of the 21 factors compared between the two stocks.